Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | LOXO-338 for the treatment of advanced hematological malignancies

Wojciech Jurczak • 11 Jun 2022
EHA 2022
General LOXO-338 Venetoclax

Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland talks on a Phase I study evaluating oral LOXO-338, a selective BCL2 inhibitor, for the treatment of patients with advanced hematological malignancies (NCT05024045). Prof. Jurczak discusses the importance of developing other BCL2 inhibitors and the future implications of this research. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Wojciech Jurczak

Nemtabrutinib in R/R follicular lymphoma
1:13
Nemtabrutinib in R/R follicular lymphoma
Wojciech Jurczak • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Wojciech Jurczak • 6 Dec 2025
BRUIN CLL-313 results: pirtobrutinib versus BR in patients with treatment-naive CLL/SLL
5:17
BRUIN CLL-313 results: pirtobrutinib versus BR in patients with treatment-naive CLL/SLL
Wojciech Jurczak • 6 Dec 2025
Treating R/R CLL: the value of BTKis and venetoclax
1:59
Treating R/R CLL: the value of BTKis and venetoclax
Wojciech Jurczak • 27 Sep 2024

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals